ЦИСТАТИН С В СОВРЕМЕННОЙ МЕДИЦИНЕ
https://doi.org/10.24884/1561-6274-2012-16-1-22-39
Аннотация
В обзоре рассмотрены возможности применения эндогенного индикатора функционального состояния почек – цистатина С (Цис С). Дана оценка результатам использования Цис С как маркера скорости клубочковой фильтрации (СКФ) у взрослых и детей. Проанализированы перспективы применения этого параметра в диагностике острого повреждения почек. Оценена также целесообразность его использования в кардиологии и диабетологии. Имеющиеся данные позволяют полагать, что это соединение может давать довольно объективную оценку величины СКФ. При этом, Цис С, по-видимому, несколько превосходит другие рутинные методы определения СКФ в у детей и пациентов с сахарным диабетом. Тем не менее, результаты применения Цис С в клинической практике не однозначны и требуют дальнейших исследований.
Об авторах
И. Г. Каюков
Санкт-Петербургский государственный медицинский университет им акад. И.П. Павлова
Россия
Россия
Научно-исследовательский институт нефрологии
кафедра нефрологии и диализа
197022, Санкт-Петербург, ул. Л. Толстого, д. 17. Тел.: (812)- 346-39-26
А. В. Смирнов
Санкт-Петербургский государственный медицинский университет им акад. И.П. Павлова
Россия
Россия
Научно-исследовательский институт нефрологии
кафедра пропедевтики внутренних болезней
В. Л. Эмануэль
Санкт-Петербургский государственный медицинский университет им акад. И.П. Павлова
Россия
кафедра клинической лабораторной диагностики
Россия
кафедра клинической лабораторной диагностики
Список литературы
1. National Kidney Foundation KD: Clinical practice guidelines for chronic Kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002: 39 [Suppl 1]: S1-S266
2. Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 11-17
3. Смирнов АВ, Каюков ИГ, Есаян АМ, Добронравов ВА, Кучер АГ, Тугушева ФА. Превентивный подход в современной нефрологии. Нефрология 2004; 8(3): 7-14
4. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67(6): 2089-20100;
5. Levey AS, de Jong PE, Coresh J et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2010; http:/www. kidney-international.org]
6. Kasiske BL, Keane WF. Laboratory assessment of renal disease: clearance, urinalysis, and renal biopsy. In: Brenner BM, ed. The kidney, fifth ed., Brenner&Rector, W.B. Saunders, 1998; 21477-22269
7. Carlson JA, Harrington JT. Laboratory evaluation of renal function. In: Schrier RW, Gottschalk CW, eds. Disease of the kidney, fifth ed. Little, Brown&Co, Boston e.a., 1993; 361-405
8. Perrone R, Steinman TI, Beck GJ et al. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA and inulin. The Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1990; 16: 224-235
9. Levey AS, Greene T, Schluchter MD et al. Glomerular filtration rate measurement in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993; 4: 1159-1171
10. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992; 38: S20-S27
11. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004;41(5-6):467-550
12. Mareš J, Stejskal D, Vavrauškova J et al. Use of cystatin C determination in clinical diagnostics. Biomed Papers 2003; 147(2): 177-180
13. Lie MA, Locs BG, Henskens YM et al. Salivary cystatin activity and and cystatin C in natural and experimental gingivitis in smokers and non-smokers. J Clin Periodontol 2001; 28: 979-984
14. Uchida К, Goton A. Measurements of cystatin-C and creatinine in urine. Clin Chim Acta 2002; 323 (1-2): 121-128
15. Tkaczyk M, Nowicki M, Lukamowicz J. Increased cystatin C concentration in urine of nephrotic children. Pediatr Nephrol 2004; 19(11): 1278-1280
16. Herget-Rosental S, Feldcamp T, Volbracht L, Kribben A. Measurement of urinary cystanin C by particle-enhanced nephelometric immunoassay: precision, interference, stability and reference range. Ann Clin Biochem 2004; 41(Pt 2): 111-118
17. Herget-Rosental S, Poppen D, Husing J et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004b; 50: 552-558
18. Hellerstein S, Berenbom M, Erwin P et al. The ratio of urinary cystatin C to urinary creatinine for detection decreased GFR. Pediatr Nephrol 2004; 19(5): 521-525
19. Abrahamson M, Olafsson I, Palsdottir A et al. Structure and expression of the human cystatine C gene. Biochem J 1990; 268: 287-294
20. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystain C (γ-trace) as a measure of glomerular filtration rate. Scand J Clin Lab Invest 1985; 45: 97-101
21. Grubb A, Simonsen O, Sturfelt G et al. Serum concentration of cystatin C, factor D and β2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 1985; 218: 499-503
22. Tian S, Kusano E, Ohara T et al. Cystatin C measurement and its practical use in patients with various renal diseases. Clin Nephrol 1997; 48(2): 104-108
23. Randers E, Kristensen JH, Erlandsen EJ, Danielsen H. Serum cystatin C as a marker of the renal function. Scand J Clin Lab Invest 1998; 58(7):585-592
24. Rodrigo E, Martin de Francisco AL, Escallada R et al. Measurement of renal function in pre-ESRD patients. Kidney Int 2002; 61[Suppl 80]: S11-S17
25. Takuwa S, Ito Y, Ushijima K, Uchida K. Serum cystatin-C values in children by age and their fluctuation during dehydration. Pediatr Int 2002; 44(1): 28-31
26. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40(2): 221-226
27. Filler G, Bokenkamp A, Hofmann W et al. Cystatin C as a marker of GFR – history, indications, and future research. Clin Biochem 2005; 38 (1): 1-8
28. Laterza OF, Price CP, Scott MG. Cystatin C: improved estimator of glomerular filtration rate? [Review]. Clin Chem 2002; 48: 669-707
29. Gokkusu CA, Ozden TA, Gul H, Yildiz A. Relationship between plasma Cystatin C fnd creatinine in chronic renal diseases and Tx-transplant patients. Clin Biochem 2004; 37(2): 94-97
30. Štabuc B, Vrhovec L, Štabuc-Šilin M, Cizey TE. Improved prediction of decreased creatinine clearance by serum cystatin C: Use in cancer patients before and during chemotherapy. Clin Chem 2000; 46 (2): 193-197
31. Hermida J, Romero R, Tutor JC. Relationship between cestatin C and creatinine in kidney-liver transplant patients. Clin Chim Acta 2002; 316(1-2): 165-170
32. Shimizu-Tokiwa A, Kobata M, Io H et al. Serum cystatin C is more sensitive marker jf glomerular function than serum creatinine. Nephron 2002; 92(1): 224-226
33. Akbas SH, Yavuz A, Tuncer M et al. Serum cystatin C as an index of renal function in kidney transplant patients. Transplant Proc 2004; 36(1): 99-101
34. Al-Tondary YA, Hammad AM, Zaghloul YM et al. Pretreatment cystatin C in children with malignancy: can it predict chemotherapy-induced glomerular filtration rate reduction during induction phase? J Pediatr Hematol Oncol 2004; 26(6): 336-341
35. Wasen E, Isoaho R, Mattila K et al. Estimation of glomerular filtration rate in the elderly: a combination of creatinine-based formulae with serum cystatin C. J Intern Med 2004; 256 (1): 70-78
36. Podracka L, Feber J, Lepage N, Filler G. Intra-individual variation of cystatin C and creatinine in pediatric solid organ transplant recipietnts. Pediatr Transplant 2005; 9(1): 28-32
37. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003; 18: 2024-2031
38. Larsson A, Malm J, Crubb A, Hansson L.O. Calculation of glomerular filtration rate expressed in ml/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004; 64(1): 25-30
39. Woitas RP, Stoffel-Wagner B, Flommersfeld S et al. Correlation of serum cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000; 46 (5): 712-715
40. Samyn M, Cheeseman P, Bevis L et al. Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. Liver Transpl 2005; 11(3):344-349
41. Newman DJ, Thakkar H, Edwards RG et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47(1):312-318
42. Helin I, Axenram M, Grubb A. Serum cystatin C as a determinant of glomerular filtration rate in children. Clin Nephrol 1998; 49(4): 221-225
43. Rich L, Blumberg A, Huber A. Rapid and accurate assessment of glomerular filtration rate in patients with renal transplantation using serum cystatin C. Nephrol Dial Transplant 1999; 14: 1991-1996
44. Hojs R, Bevic S, Antolinc B, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in the elderly. Int J Clin Pharmacol Res 2004; 24(2-3): 49-54
45. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Kidney function estimating equations in patients with chronic kidney disease. Int J Clin Pract 2011; 65(4):458-464
46. Bargnoux AS, Cavalier E, Cristol JP et al. Cystatin C is a reliable marker for estimation of glomerular filtration rate in renal transplantation: validation of a new turbidimetric assay using monospecific sheep antibodies.Clin Chem Lab Med 2011; 49(2):265-270
47. Brondén B, Eyjolfsson A, Blomquist S et al. Dardashti A, Ederoth P, Bjursten H. Evaluation of cystatin C with iohexol clearance in cardiac surgery. Acta Anaesthesiol Scand 2011;55(2):196-202
48. Bölke E, Schieren G, Gripp S, et al. Cystatin C – a fast and reliable biomarker for glomerular filtration rate in head and neck cancer patients. Strahlenther Onkol 2011;187(3):191-201
49. Cha RH, Lee CS, Lim YH et al. Clinical usefulness of serum cystatin C and the pertinent estimation of glomerular filtration rate based on cystatin C. Nephrology (Carlton) 2010;15(8):768-776
50. Bonjoch A, Bayés B, Riba J, Puig J et al. Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. Antiviral Res 2010;88(3):347-354
51. van Deventer HE, Paiker JE, Katz IJ, George JA. A comparison of cystatin C- and creatinine-based prediction equations for the estimation of glomerular filtration rate in black South Africans. Nephrol Dial Transplant 2011;26(5):1553-1558
52. Нarmoinen A, Lehtimaki T, Korpela M et al. Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft-Gault and Levey (MDRD) formulas. Clin Chem 2003; 49(7): 1223-1225
53. Schuck O, Teplan V, Jabor A et al. Glomerular filtration rate estimation in patients with advanced chronic renal insufficiency based on serum cystain C levels. Nephron Clin Pract 2003; 93(4): 122-123
54. Schuck O, Teplan V, Sibova J, Stollova M. Predicting the glomerular filtration rate from serum creatinine, serum cystatin C and the Cockcroft and Gault formula with regard to drug dosage adjustment. Int J Clin Pharmacol Ther 2004; 42(2): 97-93
55. Oddoze C, Morange S, Portugal H et al. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis 2001; 38: 310-316
56. Chantrel F, Agin A, Offner M et al. Comparison of cystatin C versus creatinine for detection of mild renal failure. Clin Nephrol 2000; 54: 374-381
57. Shastri S, Katz R, Shlipak MG, et al. Cystatin C and Albuminuria as Risk Factors for Development of CKD Stage 3: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2011 Feb 4. [Epub ahead of print]
58. Plebani M, Dall’Amico R, Mussap M et al. Is serum cystatin C a sensitive marker of glomerular filtration rate (GFR)? A preliminary study on renal transplant patients. Ren Fail 1998; 20(2): 303-309
59. Peralta CA, Katz R, Sarnak MJ et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22(1):147-155
60. Foley RN, Wang C, Collins AJ. Cystatin C, mortality risk and clinical triage in US adults: threshold values and hierarchical importance. Nephrol Dial Transplant 2010 Oct 20. [Epub ahead of print]
61. Tsai JP, Wu SW, Hung TW et al. Diagnostic performance of serum cystatin C and serum creatinine in the prediction of chronic kidney disease in renal transplant recipients. Transplant Proc 2010; 42(10):4530-4533
62. Finney Н, Newman DJ, Gruber W et al. Initial evaluation of cystanin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 1997; 43: 1016-1022
63. Kyhse-Andersen J, Schmidt C, Nordin G et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994; 40(10):1921-1926
64. Podracka L, Feber J, Lepage N, Filler G. Intra-individual variation of cystatin C and creatinine in pediatric solid organ transplant recipietnts. Pediatr Transplant 2005; 9(1): 28-32
65. Keevil BG, Kilpatrick ES, Nichols SP, Maylor PW. Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. Clin Chem 1998; 44: 1535-1539
66. Tangri N, Stevens LA, Schmid CH et al. Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate. Kidney Int 2011;79(4):471-477
67. Bokenkamp M, Domanetzki M, Zinck R et al. Cystatin C serum concentration underestimate glomerular filtration rate in renal transplant patients. Clin Chem 1999; 45: 1866-1868
68. Fanos V, Mussap M, Plebani M, Cataldi L. Cystatin C in paediatric nephrology. Present situation and prospects. Minerva Pediatr 1999; 51 (5): 167-177
69. Bjarnadottir M, Crubb A, Olafsson I. Promoter-mediated dexamethasone-indused increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest 1995; 55: 617-623
70. Risch L, Herklotz R, Blumberg A, Huber AR. Effects of glucocorticoid immunosupression on serum cystatin C concentration in renal transplant patients. Clin Chem 2001; 47: 2055-2059
71. Cimerman N, Brgurjan PM, Krasovec M et al. Serum cystatin C, a potent inhibitor of cysteine proteinase, is elevated in asthmatic patients. Clin Chim Acta 2000; 300: 83-95
72. Watanabe S, Okura T, Liu J et al. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res 2003; 26 (11): 895-899
73. Kos J, Štabuc B, Cimerman N, Brunner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression [Letter]. Clin Chem 1998; 44: 2556-2557
74. Bagshaw SM, Bellomo R. Cystatin C in acute kidney injury. Curr Opin Crit Care 2010 Aug 21. [Epub ahead of print]
75. Herget-Rosental S, Marggraf G, Husing J et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004c; 66 (3): 1115-1122
76. Endre ZH, Pickering JW, Walker RJ et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int 2011; 79(10):1119-1130
77. Bell M, Granath F, Mårtensson J et al. Cystatin C is correlated with mortality in patients with and without acute kidney injury. Nephrol Dial Transplant 2009 24(10): 3096-3102
78. Chung MY, Jun DW, SungSA. Diagnostic value of cystatin C for predicting acute kidney injury in patients with liver cirrhosis. Korean J Hepatol 2010; 16(3): 301-307
79. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005;9(3): 7-15
80. Ronco C, McCullough P, Anker SD, Anand I et al. Cardiorenal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010; 31(6): 703-711
81. McCullough PA. Cardiorenal syndromes: Pathophysiology to prevention. Int J Nephrol 2011; 2011: 762590. doi: 10.4061/2011/762590]
82. Смирнов АВ, Седов ВМ, Лхаахуу Од-Эрдэнэ, Каюков ИГ и др. Снижение скорости клубочковой фильтрации как независимый фактор риска сердечно-сосудистой болезни. Нефрология 2006; 10(4): 7-17
83. Majunath G, Tighionart H, Ibrahim H et al. Level of kidney function as a risk factors for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47- 55
84. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62: 1402-1407
85. Nitsch D, Dietrich DF, von Eckardstein A et al. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study. Nephrol Dial Transplant 2006; 21(4): 935-944
86. Segura J, Campo C, Ruilope LM. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int 2004; [Suppl 92]:S45-S49
87. Mann JFE. Cardiovascular risk in patients with mild renal insufficiency: implication for the use of ACE inhibitors. La Presse Medicale 2005; 34(18): 1303-1308
88. Vanholder R и соавт. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20(6):1048-1056
89. Levey AS, de Jong PE, Coresh J et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2010; http:/www. kidney-international.org
90. Lassus J, Harjola VP. Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev 2011; Mar 23. [Epub ahead of print]
91. Dzielinska Z, Januszewicz A, Wiecek A et al. Reduced kidney function estimated by cystatin C and clinical outcomes in hypertensive patients with coronary artery disease: association with homocysteine and other cardiovascular risk factors. Kidney Blood Press Res 2010;33(2):139-148
92. Hoke M, Amighi J, Mlekusch W et al. Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke 2010; 41(4): 674-679
93. Rifkin DE, Katz R, Chonchol M, Fried LF et al. Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant 2010; 25(5):1560-1567
94. Ge C, Ren F, Lu S, Ji F, Chen X, Wu X. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clin Cardiol 2009; 32(11): 644-648
95. Shlipak MG, Katz R, Kestenbaum B et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol 2009; 20(12): 2625-2630
96. Taglieri N, Fernandez-Berges DJ, Koenig W et al. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis 2010; 209(1): 300-305
97. Derzhko R, Plaksej R, Przewlocka-Kosmala M, Kosmala W. Prediction of left ventricular dysfunction progression in patients with a first ST-elevation myocardial infarction--contribution of cystatin C assessment. Coron Artery Dis 2009; 20(7): 453-461
98. Ichimoto E, Jo K, Kobayashi Y, Inoue T et al. Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction. Circ J 2009; 73(9):1669-1673
99. Kilic T, Oner G, Ural E et al. Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis 2009; 207(2):552-558
100. Windhausen F, Hirsch A, Fischer J et al. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem 2009; 55(6):1118-1125
101. Muntner P, Mann D, Winston J, Bansilal S, Farkouh ME. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol 2008;102(1):54-57
102. Eggers KM, Dellborg M, Oldgren J et al. Risk prediction in chest pain patients by biochemical markers including estimates of renal function. Int J Cardiol 2008; 128(2): 207-713
103. Luc G, Bard JM, Lesueur C, Arveiler D et al. Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis 2006;185(2):375-380
104. Wu CK, Chang MH, Lin JW et al. Renal-related biomarkers and long-term mortality in the US subjects with different coronary risks. Atherosclerosis 2011; Mar 1. [Epub ahead of print]
105. Nerpin E, Ingelsson E, Risérus U et al. The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly men. Nephrol Dial Transplant 2011; Feb 18. [Epub ahead of print]
106. Keller T, Messow CM, Lubos E et al. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J 2009; 30(3):314-320
107. Shlipak MG, Katz R, Sarnak MJ et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145(4):237-246
108. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352(20):2049-2060
109. Deo R, Fyr CL, Fried LF et al. Kidney dysfunction and fatal cardiovascular diseasean association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J 2008; 155(1): 62-68
110. Beilby J, Divitini ML, Knuiman MW et al. Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population. Clin Chem 2010; 56(5):799-804
111. Naruse H, Ishii J, Kawai T, Hattori K et al. Cystatin C in acute heart failure without advanced renal impairment. Am J Med 2009; 122(6): 566-573
112. Menon V, Shlipak MG, Wang X et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007;147(1):19-27
113. Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin c concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005;142:497–505
114. Djousse L, Kurth T, Gaziano JM. Cystatin c and risk of heart failure in the physicians‘ health study (phs). Am Heart J 2008; 155: 82–86
115. Ärnlöv J. Diminished renal function and the incidence of heart failure. Curr Cardiol Rev 2009; 5(3): 223–227
116. Moran A, Katz R, Smith NL, et al. Cystatin c concentration as a predictor of systolic and diastolic heart failure. J Card Fail 2008; 14: 19–26
117. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin c with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: Data from the heart and soul study. Circulation 2007; 115: 173–179]
118. Jernberg T, Lindahl B, James S, Larsson A et al. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004;110(16):2342-2348]
119. Melander O, Newton-Cheh C, Almgren P et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009; 302(1): 49-57]
120. Schnabel RB, Schulz A, Messow CM et al. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J 2010; 31(24):3024-3031
121. Lee M, Saver JL, Huang WH et al. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes 2010;3(6):675-683]
122. Hoke M, Amighi J, Mlekusch W et al. Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke 2010; 41(4): 674-679
123. Zhao DQ, Pan SY, Chen JH, Yang WJ. [Relationship between cystatin C and cerebral infarction]. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29(4):807-808. PubMed abstract.[Article in Chinese]
124. Ni L, Lü J, Hou LB, Yan JT et al.Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke 2007; 38(12): 3287-3288
125. Aguilar MI, O’Meara ES, Seliger S et al. Albuminuria and the risk of incident stroke and stroke types in older adults. Neurology 2010; 75(15):1343-1350
126. Shankar A, Teppala S. Relationship between serum cystatin C and hypertension among US adults without clinically recognized chronic kidney disease. J Am Soc Hypertens 2011; Apr 16 [Epub ahead of print]
127. Dzielinska Z, Januszewicz A, Wiecek A et al. Reduced kidney function estimated by cystatin C and clinical outcomes in hypertensive patients with coronary artery disease: association with homocysteine and other cardiovascular risk factors. Kidney Blood Press Res 2010;33(2):139-148
128. Okura T, Jotoku M, Irita J et al. Association between cystatin C and inflammation in patients with essential hypertension. Clin Exp Nephrol 2010;14(6):584-588
129. Mena C, Robles NR, de Prado JM, Gallego FG, Cidoncha A. Cystatin C and blood pressure: results of 24 h ambulatory blood pressure monitoring. Eur J Intern Med 2010;21(3):185-190
130. Palatini P, Benetti E, Zanier A, Santonastaso M et fl. Cystatin C as predictor of microalbuminuria in the early stage of hypertension Nephron Clin Pract 2009;113(4):309-314
131. Prats M, Font R, Bardají A, Gutierrez C et al. Cystatin C and cardiac hypertrophy in primary hypertension. Blood Press 2010;19(1):20-25]
132. Okura T, Kurata M, Irita J et al. Renal resistance index is a marker of future renal dysfunction in patients with essential hypertension. J Nephrol 2010;23(2):175-180
133. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009; 4(11):1832-1843
134. Thomas C, Thomas L. Renal failure-measuring the glomerular filtration rate. Dtsch Arztebl Int 2009; 106(51-52): 849-854
135. Finney H, Newman DJ, Thakkar H, Fell JME, Price CP: Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. Arch Dis Childh 2000; 82: 71– 75
136. Novo AC, Sadeck Ldos S, Okay TS, Leone CR. Longitudinal study of Cystatin C in healthy term newborns. Clinics (Sao Paulo) 2011;66(2):217-220
137. Nitsch D, Sandling JK, Byberg L et al. Fetal, developmental, and parental influences on cystatin C in childhood: The Uppsala Family Study. Am J Kidney Dis 2011 Mar 19. [Epub ahead of print]
138. Dworkin LD. Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertension 2001; 10: 551– 553
139. Filler G, Priem F, Lepage N et al. β-Trace protein, cystatin C, β2 -microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem 2002;48: 729– 736
140. Stickle D, Cole B, Hock K et al. Correlation of plasma concentrations of cystatin C and creatinine to inulin clearance in a pediatric population. Clin Chem 1998;44: 1334–1338
141. Filler G, Priem F, Vollmer I et al. Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate. Pediatr Nephrol 13: 501–505, 1999
142. Ylinen EA, Ala-Houhala M, Harmoinen APT, Knip M. Cystatin C as a marker for glomerular filtration rate in pediatric patients. Pediatr Nephrol 13: 506–509, 1999]
143. Blufpand HN, Tromp J, Abbink FC et al. Cystatin C more accurately detects mildly impaired renal function than creatinine in children receiving treatment for malignancy. Pediatr Blood Cancer 2011; Apr 1. doi: 10.1002/pbc.23119 [Epub ahead of print]
144. Brinkert F, Kemper MJ, Briem-Richter A et al. High prevalence of renal dysfunction in children after liver transplantation: non-invasive diagnosis using a cystatin C-based equation. Nephrol Dial Transplant 2011;26(4):1407-1412
145. Franco MC, Nagasako SS, Machado PG et al. Cystatin C and renal function in pediatric kidney transplant recipients. Braz J Med Biol Res 2009; 42(12):1225-1229
146. Berding G, Geisler S, Melter M et al. Estimation of glomerular filtration rate in liver-transplanted children: comparison of simplified procedures using 51Cr-EDTA and endogenous markers with Sapirstein’s method as a reference standard. Pediatr Transplant 2010;14(6):786-795
147. Bouvet Y, Bouissou F, Coulais Y et al. GFR is better estimated by considering both serum cystatin C and creatinine levels. Pediatr Nephrol 2006; 21: 1299–1306
148. Zappitelli M, Parvex P, Joseph L et al. Derivation and validation of cystatin C-based prediction equations for GFR in children. Am J Kidney Dis 48: 221– 230, 2006
149. Schwartz GJ, Munoz A, Schneider MF et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629–637
150. NKF-KDOKI http://www.kidney.org/professionals/kdoqi/ gfr_calculatorPed.cfm
151. Mussap M, Dalla Vestra M, Fioretto P et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002; 61:1453–1461
152. Pucci L, Triscornia S, Lucchesi D et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem 2007;53:480–488
153. Rigalleau V, Beauvieux MC, Le Moigne F et al. Cystatin C improves the diagnosis and stratification of chronic kidney disease, and the estimation of glomerular filtration rate in diabetes. Diabetes Metab 2008;34:482–489
154. El-Shafey EM, El-Nagar GF, Selim MF et al. Is serum cystatin C an accurate endogenous marker of glomerular filteration rate for detection of early renal impairment in patients with type 2 diabetes mellitus? Ren Fail 2009; 31(5):355-359
155. Chudleigh RA, Ollerton RL, Dunseath G et al.Use of cystatin C-based estimations of glomerular filtration rate in patients with type 2 diabetes. Diabetologia 2009; 52(7):1274-1278
156. Perkins BA, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005;16(5):1404–1412
157. Premaratne E, MacIsaac RJ, Finch S, et al. Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care 2008;31:971–973
158. Zhang PP, Zhan JF, Xie HL, Li LS, Liu ZH. Evaluation of glomerular filtration rate using cystatin C in diabetic patients analysed by multiple factors including tubular function. J Int Med Res 2010;38(2):473-483
159. Borges RL, Hirota AH, Quinto BM et al. Is cystatin C a useful marker in the detection of diabetic kidney disease? Nephron Clin Pract 2010; 114(2): 127-134
160. Li HX, Xu GB, Wang XJ, Zhang XC, Yang JM. Diagnostic accuracy of various glomerular filtration rates estimating equations in patients with chronic kidney disease and diabetes. Chin Med J (Engl) 2010;123(6):745-751
161. Jeon YK, Kim MR, Huh JE et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci 2011; 26(2):258-263
162. Cherney DZ, Sochett EB, Dekker MG, Perkins BA. Ability of cystatin C to detect acute changes in glomerular filtration rate provoked by hyperglycaemia in uncomplicated Type 1 diabetes. Diabet Med 2010; 27(12):1358-1365
163. Sahakyan K, Klein BE, Lee KE et al. Serum cystatin C and the incidence of hypertension in type 1 diabetes mellitus. Am J Hypertens 2011;24(1):59-63
164. Maahs DM, Snell-Bergeon JK, Hokanson JE et al. Relationship between cystatin C and coronary artery atherosclerosis progression differs by type 1 diabetes Diabetes Technol Ther 2010; 12(1):25-33
165. de Boer IH, Katz R, Cao JJ et al. Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care 2009; 32(10):1833-1838
166. Смирнов АВ, Каюков ИГ, Есаян АМ и др. Проблема оценки скорости клубочковой фильтрации в современной нефрологии: новый индикатор - цистатин С. Нефрология 2005; 9(3): 16-27
Рецензия
Для цитирования:
Каюков И.Г., Смирнов А.В., Эмануэль В.Л. ЦИСТАТИН С В СОВРЕМЕННОЙ МЕДИЦИНЕ. Нефрология. 2012;16(1):22-39. https://doi.org/10.24884/1561-6274-2012-16-1-22-39
For citation:
Kayukov I.G., Smirnov A.V., Emanuel V.L. CYSTATIN C IN CURRENT MEDICINE. Nephrology (Saint-Petersburg). 2012;16(1):22-39. (In Russ.) https://doi.org/10.24884/1561-6274-2012-16-1-22-39
Просмотров: 1058
Послать статью по эл. почте 